Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration

Stargardt's Disease Clinical Trial

Official title:
An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt's Macular Degeneration

Status Active, not recruiting

Clinical Trial Summary

Primary Objective: To evaluate the long-term safety and tolerability of SAR422459 in patients with Stargardt's Macular Degeneration. Secondary Objective: To assess: - Safety - Biological activity

Clinical Trial Description

Patients will be followed for 15 years after completion/early termination from the previous TDU13583 study (NCT01367444). As the initial TDU13583 study is terminated - recruitment to this LTS13588 study is over with 27 patients enrolled. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01736592
Study type	Interventional
Source	Sanofi
Contact
Status	Active, not recruiting
Phase	Phase 1/Phase 2
Start date	December 14, 2012
Completion date	August 29, 2033

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06435000` - An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
Recruiting	`NCT02617966` - Rod and Cone Mediated Function in Retinal Disease
Terminated	`NCT01367444` - Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration	Phase 1/Phase 2
Completed	`NCT01790958` - Microcurrent Stimulation to Treat Macular Degeneration	N/A
Completed	`NCT02903576` - Stem Cell Therapy for Outer Retinal Degenerations	Phase 1/Phase 2